Trials / Completed
CompletedNCT00727961
A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate efficacy and tolerability, and number of positive response to treatment with CAELYX (50 mg/m\^2), administered as monotherapy once per 4 weeks to patients with metastatic epithelial ovarian cancer, resistant to previous platinum therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Liposomal Doxorubicin hydrochloride | Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles |
Timeline
- Start date
- 2004-11-09
- Primary completion
- 2008-01-10
- Completion
- 2008-01-10
- First posted
- 2008-08-05
- Last updated
- 2017-06-08
- Results posted
- 2009-07-16
Source: ClinicalTrials.gov record NCT00727961. Inclusion in this directory is not an endorsement.